VAG
BCLI

VisionPoint Advisory Group’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

VisionPoint Advisory Group’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-130
Closed -$658 – 289
2024
Q2 		$658 Hold
130
– – ﹤0.01% 735
2024
Q1 		$1.1K Hold
130
– – ﹤0.01% 721
2023
Q4 		$531 Hold
130
– – ﹤0.01% 684
2023
Q3 		$389 Hold
130
– – ﹤0.01% 638
2023
Q2 		$4K Buy
+130
New +$5.39K ﹤0.01% 466

Other funds holding BCLI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

VisionPoint Advisory Group's BCLI Position: Q3 2024 in Review

VisionPoint Advisory Group sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2024, closing a stake of 130 shares — an estimated $658 sold.

VisionPoint Advisory Group first reported a position in BCLI in Q2 2023 and held it in 5 quarters. The position peaked at $4K in Q2 2023. 38 funds tracked by Wall St. Rank hold BCLI as of Q3 2024.

  • VisionPoint Advisory Group reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2024 after selling out during the quarter.
  • VisionPoint Advisory Group sold 130 BRAINSTORM CELL THERAPUTC shares in Q3 2024, an estimated $658.
  • VisionPoint Advisory Group first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2023 and held it in 5 quarters.
  • VisionPoint Advisory Group's BRAINSTORM CELL THERAPUTC position peaked at $4K in Q2 2023.
  • 38 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2024.

Based on VisionPoint Advisory Group's 13F filing for Q3 2024, filed 15 Oct 2024.